
AbbVie’s elagolix has been slated as a blockbuster-in-the-making by analysts predicting big things for the potential treatment for uterine fibroids …
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics

